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ABSTRACT
Primary infection of the immunocompromised host with the oncovirus Epstein-
Barr virus (EBV) that targets mainly B-cells is associated with an increased risk 
for EBV-associated tumors. The early events subsequent to primary infection with 
potential for B-cell transformation are poorly studied. Here, we modeled in vitro the 
primary infection by using B-cells isolated from tonsils, the portal of entry of EBV, 
VLQFHVSHFLHVVSHFL¿FLW\RI(%9KDPSHUVPRGHOLQJLQH[SHULPHQWDODQLPDOV,QFUHDVLQJ
HYLGHQFHLQGLFDWHVWKDWWKHKRVW'1$GDPDJHUHVSRQVH''5FDQLQÀXHQFHDQG
EHLQÀXHQFHGE\(%9LQIHFWLRQ7KXVZHLQRFXODWHGWRQVLOODU%FHOOV7%&VZLWK
(%9%DQGLQYHVWLJDWHGFHOOSUROLIHUDWLRQDQGWKH''5GXULQJWKH¿UVWKRXUV
WKHUHDIWHU:HLGHQWL¿HGIRUWKH¿UVWWLPHWKDW(%9LQIHFWLRQRI7%&VLQGXFHVDSHULRG
of hyperproliferation 48-96 hours post infection characterized by the activation of 
DWD[LDWHODQJLHFWDVLDDQG5DGUHOHDWHG$75DQGFKHFNSRLQWNLQDVH&KN
:KHUHDVLQKLELWLRQRI&KNGLGQRWDIIHFW%FHOOWUDQVIRUPDWLRQWKHVSHFL¿FLQKLELWLRQ
RI$75UREXVWO\GHFUHDVHGWKHWUDQVIRUPDWLRQHI¿FLHQF\RI(%92XUUHVXOWVVXJJHVW
that activation of ATR is key for EBV-induced B-cell transformation. Thus, targeting 
the interaction between ATR/Chk1 and EBV could offer new options for the treatment 
of EBV-associated malignancies.
INTRODUCTION
Environmental and endogenous challenges 
constantly endanger the integrity of the genetic 
information by inducing DNA damage. Eukaryotic 
cells have developed several powerful mechanisms 
to repair DNA damage, thereby preventing genomic 
instability and avoiding tumorigenesis [1]. Depending 
RQ WKH W\SH RI OHVLRQ VSHFL¿F '1$ GDPDJH UHVSRQVH
(DDR) protein kinases are activated. In general, single-
stranded regions of DNA coated by the replication 
protein A (RPA) promote activation of ataxia 
telangiectasia and Rad3-related (ATR) [2, 3], whereas 
DNA double-strand breaks (DSBs) recognized by the 
MRE11-RAD50-NBS1 (MRN) complex primarily 
activate ataxia telangiectasia mutated (ATM) [4, 5]. 
Downstream of ATM and ATR, phosphorylation events 
are initiated to activate a huge variety of transducer and 
effector proteins, such as the serine-threonine checkpoint 
effector kinases Chk1 and Chk2 [6]. The latter will, 
in turn, phosphorylate additional effectors proteins, 
ZKLFK FDQ LQGXFH DFWLYDWLRQ RI VSHFL¿F '1$ GDPDJH
checkpoints leading to cell cycle arrest, thereby allowing 
time for the repair of damaged DNA. This prevents DNA 
replication or cell division in the presence of damaged 
genomic material and the spreading of possible deleterious 
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mutations. Should DNA repair not be possible to prevent 
a catastrophic level of genomic instability, the DDR can 
activate different downstream pathways that result into 
programmed cell death or cell senescence and eliminate 
the potential threats.
There is increasing evidence that the oncogenic 
gammaherpesvirus Epstein-Barr virus (EBV), which 
mainly targets B-cells and establishes chronic B 
lymphocellular infection, modulates the activity of the 
cellular DDR [7–10]. In particular, Nikitin and colleagues 
showed that activation of the ATM/Chk2 signaling 
pathway after in vitro EBV infection of B-cells is critical 
for the suppression of EBV-mediated B-cell transformation 
and can act as an innate tumor suppression pathway [11]. 
EBV infects more than 95% of the world’s 
population [12]. The nasopharyngeal lymphoid system, 
including tonsils, is the portal of entry for EBV that targets 
and resides in B-cells for the life-time of the host. Thus, 
following EBV exposure, tonsillar B-cells (TBCs) are most 
OLNHO\WKH¿UVW%FHOOVWDUJHWHGE\WKHYLUXV$IWHUSULPDU\
infection, EBV establishes reversible latency in B-cells 
and persists there mostly as a long lasting asymptomatic 
infection in a rather stable pool of resting memory 
B-cells that circulate in the peripheral blood [13, 14]. 
Lytic reactivation in the nasopharynx allows host-to-host 
transmission of EBV via saliva to susceptible hosts [15]. 
Although EBV infection is harmless in the vast majority 
of cases, latent EBV infection is strongly associated with 
tumors such as endemic Burkitt’s lymphoma, Hodgkin 
lymphoma, and post-transplant lymphoproliferative 
disease (PTLD) [16]. Indeed, in vitro infection of B-cells 
with EBV results in expression of all EBV’s latency genes 
and eventually in cell transformation with the outgrowth of 
O\PSKREODVWRLGFHOOOLQHVWKXVUHÀHFWLQJ(%9¶VRQFRJHQLF
potential [17–19].
Primary EBV infection induces both a humoral 
and a cell-mediated immune response [20]. The humoral 
response mainly limits the spreading of the infectious 
virus particles blocking their binding to the cellular surface 
receptors [20, 21]. Cytotoxic T lymphocytes (CTL)s target 
and kill EBV-infected B-cells, thereby playing a key 
role in limiting their propagation. Immunocompromised 
individuals lacking a fully functional immune response, 
such as HIV-infected patients or organ transplant 
recipients, are at high risk of developing EBV-
related B-cell lymphoma. Even so, the iatrogenic 
immunosuppression necessary to avoid graft rejection in 
solid organ transplantation leads to PTLD development 
in only up to 10% of the patients [22], suggesting that in 
addition to the adaptive cellular immune responses other 
mechanisms may play an important role in preventing 
the development of EBV-associated B-cell malignancies. 
One such additional protective mechanism could be the 
QDWXUHRIWKHDFWLYDWHG''5VLQFHLWKDVEHHQLGHQWL¿HG
as a major component of the underlying tumor suppressor 
mechanism upon EBV infection [11].
Here, we investigated the DDR in TBCs in 
response to EBV inoculation. We chose TBCs since they 
DUHOLNHO\WKH¿UVWKRVW%FHOOVWREHFRQIURQWHGZLWKWKH
virus upon primary infection with EBV which, in turn, is 
associated with the highest risk for PTLD in transplant 
recipients [13].
RESULTS
7RQVLOODU%FHOOVK\SHUSUROLIHUDWHLQWKH¿UVW
hours post EBV inoculation
Peripheral blood B-cells inoculated with 
EBV in vitro manifest subsequently a phase of 
hyperproliferation of 96 hours [11]. Since palatine tonsils 
are located at the portal of entry for EBV, TBCs are most 
OLNHO\WKH¿UVW%FHOOVWREHWDUJHWHGE\(%9IROORZLQJ
primary infection of the host, i.e., in the absence of 
DGDSWLYHVSHFL¿FLPPXQLW\*LYHQWKDW7%&VDQG%FHOOV
circulating in the peripheral blood may phenotypically 
and functionally differ [23], we interrogated whether 
EBV inoculation in vitro also induces hyperproliferation 
RI LVRODWHG 7%&V 7R WKLV HQG ZH LQRFXODWHG SXUL¿HG
CD19+ TBCs with EBV-B95.8, produced in the marmoset 
B95.8 cell line exposed to 12-O-tetradecanoylphorbol-13-
acetate (TPA), at a multiplicity of infection (MOI) of 8, 
and stained the TBCs with the proliferation dye CFSE. 
We monitored the proliferation of TBCs at 48, 72, 96, 120, 
DQGKRXUVSRVWLQRFXODWLRQSLXVLQJÀRZF\WRPHWU\
)LJXUH$1RQLQRFXODWHGSXUL¿HG&'7%&VZHUH
grown for 120 hours and used as negative control (mock 
inoculation). EBV-inoculated CD19+ TBCs started to 
proliferate after 48 hours and divided more than once 
between 48 and 72 hours, as indicated by the number 
of peaks detected by CFSE staining. In addition, EBV-
inoculated CD19+ TBCs proliferated faster between 48 
and 96 hours than at later time points as indicated by a 
rapid decrease in CFSE staining (Figure 1A). In contrast, 
&'7%&VGLGQRWSUROLIHUDWHZLWKLQWKH¿UVWKRXUV
post mock-inoculation. Thus, EBV induces proliferation of 
CD19+ TBCs in vitro that peaks between 48 and 96 hours 
post inoculation. 
Next, we wanted to investigate whether proliferating 
TBCs undergo a phase of hyperproliferation similar to the 
one reported for peripheral blood B-cells [11]. Thus, we 
further analyzed data from the CFSE staining experiments 
(Figure 1A) as suggested by Hawkins et al.>@%ULHÀ\
ZHFDOFXODWHGWKHPHDQGLYLVLRQQXPEHU0'1¿WWLQJD
*DXVVLDQGLVWULEXWLRQWRWKHSUHFXUVRUQRUPDOL]HGQXPEHU
of cells in each division. For each TBC donor, we plotted 
the MDN versus the analyzed time point (Figure 1B). The 
slope of this function represents the number of divisions 
per hour and inversely correlates with the proliferation 
rate. The proliferation rate of TBCs decreased over time 
(Figure 1B), indicating that cells hyperproliferated between 
48 and 96 hours after EBV inoculation but not thereafter.
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Taken together, these data demonstrate that CD19+ 
TBCs behave similarly to circulating peripheral blood 
B-cells, undergoing a phase of hyperproliferation during 
WKH¿UVWGD\VKRXUVSRVWin vitro EBV inoculation.
EBV induces activation of the ATR/Chk1 
pathway in tonsillar B-cells
Cellular hyperproliferation implicates augmented 
frequency of DNA replication, which can lead to high 
levels of DNA damage resulting in so called replication 
stress [25]. ATR and its downstream effector kinase Chk1 
are both key players in the cellular response to DNA 
replication stress [26, 27]. 
To investigate if ATR and Chk1, as to be expected 
during hyperproliferation, are activated in TBCs in 
the observed hyperproliferation phase following EBV 
inoculation, we measured their protein expression and 
SKRVSKRU\ODWLRQ OHYHOV LQ SXUL¿HG&'7%&V DW 
48, 72, and 96 hours post EBV inoculation by western 
blotting (Figure 2A). As positive and negative controls, 
we used EBV-induced lymphoblastoid cell lines (LCLs) 
treated with etoposide, a DNA topoisomerase II inhibitor 
known to induce DSBs and SSBs and mock-inoculated 
SXUL¿HG&'7%&VKDUYHVWHGKRXUVSRVWLVRODWLRQ
respectively. We detected a gradual increase in the 
phosphorylation of ATR at serine 428 (pATR) and of 
Chk1 at serine 345 (pChk1) during the course post EBV 
inoculation, with a robust signal for pChk1 at 72 hours 
(Figure 2A and 2B). This period coincided with the 
previously observed hyperproliferation phase (Figure 1B), 
suggesting that indeed EBV-inoculated TBCs experience 
replication stress during the hyperproliferation phase 
observed between 48 to 96 hours post EBV inoculation. 
Remarkably, we also observed a strong increase in total 
ATR and Chk1 protein levels already at 24 hours after 
EBV inoculation (Figure 2A). Increased ATR and Chk1 
protein levels can be triggered either by increased de novo 
transcription and translation of the protein, by decreased 
protein degradation or by increased protein stability 
[28, 29]. Furthermore, analysis of both ATR and Chk1 
mRNA expression levels by real-time quantitative PCR 
(Figure 2C) showed an increased mRNA expression for 
both ATR and Chk1 starting already at 24 hours post EBV 
inoculation. This suggested that the increase in total ATR 
and Chk1 protein levels was rather due to increased de 
novo transcription and translation rather than decreased 
protein degradation.
Kaneko et al. [29] showed that expression of Chk1 
LVLQFUHDVHGVSHFL¿FDOO\DWWKH6WR0SKDVHRIWKHFHOO
cycle at both the RNA and protein levels, whereas ATR 
seems to be expressed throughout the cell cycle at constant 
levels [30]. Indeed, in our analysis of the cell cycle of 
EBV inoculated TBCs by PI staining we found an increase 
LQWKH6*0SRSXODWLRQVWDUWLQJDWKRXUVSRVW(%9
inoculation (Figure 2D and Supplementary Figure S1A). 
This explained, at least in part, why we documented such 
a strong increase in Chk1 expression.
Figure 1: EBV induces hyperproliferation of tonsillar B-cells (TBCs) within 72 hours post inoculation. (A) Representative 
GDWD'RQRUIURP)LJXUH%RI&)6(SUROLIHUDWLRQSUR¿OHRI7%&VDWVHTXHQWLDOGD\VSRVW(%9% LQRFXODWLRQ1RQLQRFXODWHG
CD19+ B-cells harvested 120 hours post isolation (Mock) were used as negative control. (B) Mean division number of TBCs at sequential 
days post EBV-B95.8 inoculation. The function depicted as a black dashed line represents the average mean division number (MDN) for 
each time point measured. . Results shown are from TBCs from 7 donors.
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Collectively, the observed chronological correlation 
between hyperproliferation and activation of the ATR/
Chk1 pathway together with an accumulation of cells in 
6*0SKDVHIXUWKHUVWUHQJWKHQVWKHQRWLRQWKDW7%&V
experience a phase of replication stress early after EBV 
LQRFXODWLRQ LQ WKLV V\VWHPZLWK WKH DEVHQFH RI VSHFL¿F
adaptive immunity.
EBV does not induce activation of the ATM/
Chk2 pathway in tonsillar B-cells
Besides ATR/Chk1, a second kinase signaling 
cascade consists of the ATM and Chk2 protein kinases, 
which are mainly activated by DSBs rather than 
replication stress [31]. Furthermore, activation of Chk2 
has been reported to occur following EBV infection of 
peripheral blood B-cells in vitro [11]. Therefore, we 
analyzed activation of ATM and Chk2 in the identical 
samples shown in Figure 2. Similar to ATR and Chk1, 
we also noted a robust increase in total ATM and Chk2 
protein levels 24 hours after EBV inoculation (Figure 3A), 
FRQ¿UPHG E\ DQDO\VLV RI ERWK$70 DQG&KNP51$
expression levels by real-time quantitative PCR (Figure 
3D). In addition, we also detected a low activation 
of pATM and pCHk2 especially 24 hours post EBV 
inoculation (Figure 3A). However, the activation was 
limited compared to the etoposide control (Figure 3B) 
and did not affect activation of the ATM substrate KAP1 
(pKAP1 at serine 824) that controls DSB repair in 
heterochromatin [32] (Figure 3C). Interestingly, similarly 
to ATM and Chk2, we could also observe an increase of 
both total KAP1 protein levels and mRNA expression 
Figure 2: EBV inoculation elicits ATR/Chk1-mediated DDR activation in tonsillar B-cells (TBCs). TBCs where inoculated 
with EBV-B95.8 (MOI 8). (A) Cells were harvested at the indicated time points and expression of total ATR and Chk1 and pATR S428 or 
pChk1 S345 was analyzed by western blotting. Non-inoculated TBCs at 24 hours post isolation were used as negative control. Lymphoblastoid 
cell lines (LCLs) treated with Etoposide for 6 hours served as positive control. The results shown are representative of 3 independent 
experiments (B$75DQG&KNSKRVSKRU\ODWLRQZDVTXDQWL¿HGE\GHQVLWRPHWULFDQDO\VLV'DWDDUHUHSUHVHQWHGDVUDWLRRISKRVSKRU\ODWHG
WRWRWDO4XDQWL¿FDWLRQZDVSHUIRUPHGXVLQJWKHVRIWZDUHLPDJH-W7KHUHVXOWVVKRZQDUHUHSUHVHQWDWLYHRILQGHSHQGHQWH[SHULPHQWV
(C) ATR and Chk1 mRNA expression was determined in EBV-inoculated B-cells at the indicated time points by RTqPCR relative to 18S 
RNA and shown as fold change relative to non-inoculated cells. Data are presented as mean ± SEM of 4 donors. (D&HOOSRSXODWLRQLQ*
6*0DWGLIIHUHQWWLPHSRLQWVSRVW(%9LQRFXODWLRQZHUHTXDQWL¿HGE\ÀRZF\WRPHWU\EDVHGFHOOF\FOHDQDO\VLVPHDVXUHGE\ODEHOLQJ
WKH¿[HGFHOOVZLWKSURSLGLXPLRGLGH3,5HVXOWVVKRZQDUHIURPGRQRUVDQGDUHSUHVHQWHGDVPHDQ
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levels (Figure 3C and 3D) post EBV inoculation. The 
absence of KAP1 activation strongly supports the absence 
of ATM/CHk2 pathway activation in TBCs following EBV 
inoculation. Nevertheless, the observed limited activation 
of ATM and Chk2 could explain previous reports on the 
activation of the ATM pathway by EBV. 
Taken together, these results document that the 
$70&KNSDWKZD\LVQRWDFWLYDWHGLQSXUL¿HG&'
TBCs inoculated with EBV in vitro.
EBV activates the ATR/Chk1 pathway also in 
peripheral blood B-cells
*LYHQ WKDW (%9 LQIHFWLRQ RI SHULSKHUDO EORRG
B-cells in vitro was reported to activate ATM and Chk2 
but the activation of ATR and Chk1 was not referred to 
[11], we interrogated whether activation of the ATR/
Chk1 dependent pathway is dependent or independent 
of the infected B-cell origin, i.e., tonsil versus peripheral 
EORRG7KXVZHSXUL¿HG&'SHULSKHUDO%FHOOVDQG
inoculated them with EBV-B95.8 similarly as isolated 
CD19+ TBCs. We then monitored the protein expression 
and phosphorylation levels of ATR, Chk1, ATM and 
Chk2 at 24, 48, 72, and 96 hours post EBV inoculation by 
western blotting (Figure 4A and 4B). Similarly to TBCs 
(Figures 2A and 3A), we observed activation of the ATR/
Chk1 dependent pathway in peripheral blood B-cells 
following EBV inoculation, indicated by a reproducible 
increase of the phosphorylation for both ATR and Chk1 
(Figure 4A and 4C). This suggested that activation of 
ATR and Chk1 following EBV inoculation in vitro is not 
dependent on the origin of the B-cells. 
Surprisingly, in contrast to what was reported we did 
not detect activation of the ATM/Chk2 dependent pathway 
in peripheral blood B-cells following EBV inoculation 
(Figure 4B and 4C) except for a minimal increase of the 
ATM total-to-phosphorylation ratio after EBV infection 
similar to what we observed in TBCs
(Figure 3B). This suggested that distinct 
experimental procedures in the reported study [11] versus 
our study were likely responsible for the contrasting 
results in terms of ATM/Chk2 activation in peripheral 
blood B-cells. 
Activation of ATR/Chk1 is not EBV-strain 
dependent
Next, we interrogated whether activation of the ATR/
Chk1 signaling pathway in CD19+ TBCs is dependent on 
the strain of EBV used for inoculation. To this end, we 
monitored Chk1 and Chk2 phosphorylation following 
inoculation of TBCs with two distinct EBV strains. We 
LQRFXODWHGSXUL¿HG&'7%&VZLWK(%9%RUZLWK
(%9*)3SURGXFHGLQ+(.FHOOV&RQVLVWHQWZLWKRXU
previous results, we observed that pChk1, but not pChk2, 
was induced at 72 hours post-inoculation either with 
(%9%RUZLWK(%9*)3)LJXUH$
Thus, activation of the ATR/Chk1 pathway in TBCs 
following inoculation is not an EBV strain-dependent 
phenomenon, at least not with the two strains tested. 
+\SHUSUROLIHUDWLRQRI&'+ TBCs induced by 
CD40L activates Chk1
Since ATR/Chk1 activation does not seem to be 
(%9VWUDLQ VSHFL¿F ZH DVNHG ZKHWKHU WKH REVHUYHG
activation of ATR/Chk1 was EBV-dependent at all. Thus, 
we wondered whether CD40L, a B-cell stimulant with 
similar effects as EBV regarding B-cell survival and 
hyperproliferation [33], did also activate ATR/Chk1. To 
answer this question, we used CD40L in combination 
with IL-4 to stimulate proliferation of TBCs similar to 
the one observed in EBV-infected B-cells but in an EBV-
LQGHSHQGHQW IDVKLRQ:H WUHDWHGSXUL¿HG&'7%&V
with CD40L in combination with IL-4 for 72 hours and 
measured the levels of, pATR, pChk1, pATM and pChk2 
by western blotting. Indeed, inoculation of isolated CD19+ 
TBCs with CD40L resulted in activation of ATR and Chk1 
at 72 hours post stimulation (Figure 5B). 
Thus, considering that peripheral blood B-cells 
undergo a phase of hyperproliferation at 72 hours post 
CD40L stimulation [33], activation of the ATR/Chk1-
dependent pathway seems not to be a strictly EBV-related 
phenomenon in B-cells but rather seems to be linked to the 
hyperproliferation of the B-cells. 
To verify if activation of the ATR/Chk1 pathway is 
dependent from productive EBV infection or rather form 
(%9RUFHOOXODUFRPSRQHQWVWKDWPLJKWKDYHFRSXUL¿HG
with the virus, we monitored ATR, Chk1, ATM and Chk2 
IROORZLQJ LQRFXODWLRQ RI SXUL¿HG &' 7%&V ZLWK
EBV-B95.8 or UV-inactivated EBV-B95.8. Contrasting 
with ATR/Chk1 activation following inoculation with 
live EBV-B95.8, UV-inactivated EBV-B95.8 did not 
show any phosphorylation of ATR and Chk1 (Figure 
5C). This demonstrated that the UV-inactivated EBV 
does not activate ATR/Chk1-dependent pathway as live 
EBV, excluding that other elements present in the viral 
supernatant are responsible for Chk1 activation. Thus, 
TBCs need to experience EBV infection rather than 
mere contact with EBV or its elements to manifest ATR/
Chk1 activation during hyperproliferation following EBV 
inoculation (Figure 1A).
7DNHQ WRJHWKHU WKHVH UHVXOWV FRQ¿UP WKDW
K\SHUSUROLIHUDWLRQ LV VXI¿FLHQW WR LQGXFH DFWLYDWLRQ RI
$75&KNLQSXUL¿HG&'%FHOOV7KLVLQWXUQPD\
indicate that B-cells counteract their vulnerable phase of 
primary EBV infection mirrored by hyperproliferation by 
activating the ATR/Chk1-related pathway.
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ATR activation increases EBV-mediated 
transformation of TBCs
EBV has the ability to transform B-cells in vitro 
[13, 34]. Thus, we were interested to know whether 
DFWLYDWLRQRI WKH VSHFL¿F$75&KNPHGLDWHGSDWKZD\
within 96 hours post EBV inoculation in vitro has any 
consequences for the subsequent transformation of TBCs, 
since the risk for PTLD in transplant recipients is highest 
following primary EBV infection but is also present in 
EBV carriers [22].
0RUHVSHFL¿FDOO\ZHPLPLFNHGWKHin vivo situation 
of primary EBV B-cell infection in iatrogenically 
immunosuppressed transplant recipients by using 
WRQVLOODUPRQRQXFOHDUFHOOV70&VUDWKHUWKDQSXUL¿HG
CD19+ TBCs, from EBV seronegative donors, to mimic 
Figure 3: EBV inoculation does not elicit ATM/Chk2-mediated DDR activation in tonsillar B-cells (TBCs). TBCs 
where inoculated with EBV-B95.8 (MOI 8). Non-inoculated TBCs at 24 hours post isolation were used as negative control (uninfected). 
Lymphoblastoid cell lines (LCLs) treated with Etoposide for 6 hours served as positive control. (A) Cells were harvested at the indicated 
time points, and expression of total ATM or Chk2 and pATM S1981 or pChk2 T68 was analyzed by western blotting. (B) ATM and Chk2 
SKRVSKRU\ODWLRQDQGWRWDOSURWHLQDPRXQWZHUHTXDQWL¿HGE\GHQVLWRPHWULFDQDO\VLV'DWDDUHUHSUHVHQWHGDVUDWLRRISKRVSKRU\ODWHGWR
WRWDO4XDQWL¿FDWLRQZDVSHUIRUPHGXVLQJWKHVRIWZDUHLPDJH-WC) Total KAP1 and pKAP1 S824 was analyzed by western blotting. 
The results shown are representative of 3 independent experiments. (D) ATM, Chk2 and KAP1 mRNA expression was determined in EBV-
inoculated B-cells at the indicated time points by RTqPCR relative to 18 S RNA and shown as fold change relative to non-inoculated cells. 
Data are presented as mean ± SEM of 4 donors. 
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Figure 4: EBV inoculation elicits ATR/Chk1-mediated pathway activation but not ATM/Chk2 in peripheral B-cells 
(PBCs). Peripheral B-cells were inoculated with EBV-B95.8 (MOI 8). Non-inoculated peripheral B-cells at 24 hours post isolation served 
as negative control (Uninfected), Lymphoblastoid cell lines (LCLs) derived from TMCs or PBMCs treated with Etoposide for 1 hours 
served as positive control. Detection of MRE11 served as loading control. (A) Cells were harvested at the indicated time points and 
expression of total ATR or Chk1 and pATR S428 or pChk1 S345 was analyzed by western blotting. (B) Cells were harvested at the indicated 
time points, and expression of total ATM or Chk2 and pATM S1981 or pChk2 T68 was analyzed by western blotting. The results shown are 
representative of 3 independent experiments. (C$75$70&KNDQG&KNSKRVSKRU\ODWLRQDQGWRWDOSURWHLQDPRXQWZHUHTXDQWL¿HGE\
GHQVLWRPHWULFDQDO\VLV'DWDDUHUHSUHVHQWHGDVUDWLRRISKRVSKRU\ODWHGWRWRWDO4XDQWL¿FDWLRQZDVSHUIRUPHGXVLQJWKHVRIWZDUHLPDJH-
1.49t. * = Not detectable.
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primary host EBV infection. We also used TMCs from 
EBV seropositive donors treated with cyclosporine 
A to suppress T cell function, to mimic primary B-cell 
infection in immunosuppressed EBV carriers. We used 
WZRGLVWLQFWLQKLELWRUV9(VSHFL¿FIRU$75$75L
>@ DQG &+,5 VSHFL¿F IRU &KN &KNL >@
6SHFL¿FLW\RI9(DQG&+,5ZHUHDVVHVVHGE\
monitoring the phosphorylation levels of Chk1 at S345 
and S296 [37] respectively (Supplementary Figure 
S2A and S2B). To avoid artifacts that may result from 
inhibitors toxicity we also assessed the cell viability 
after treatment with VE-821 and CHIR-124 at different 
concentration (Supplementary Figure S2C).
TMCs were treated with ATRi or Chk1i from 
the start of the inoculation (day 0 pi) or whilst in the 
K\SHUSUROLIHUDWLRQ SKDVH  GD\V SL 6SHFL¿FDOO\
we inoculated TMCs with decreasing MOIs of EBV 
according to a 3-fold serial dilution. At 5 weeks pi, we 
GHWHUPLQHGWKH(%9WUDQVIRUPDWLRQHI¿FLHQF\E\FRXQWLQJ
the number of wells positive for B-cells outgrowth. The 
percentage of transformed wells was plotted relative to 
the transforming units (TU) of EBV used per well. TUs 
per well were calculated assuming that 62.5% of wells 
ZHUH WUDQVIRUPHG E\  78 7UDQVIRUPDWLRQ HI¿FLHQF\
was assessed comparing how many TUs were needed 
to transform 62.5% of wells. ATR inhibition at day 0 or 
)LJXUH+\SHUSUROLIHUDWLRQRI&'7%&VLQGXFHGE\&'/DFWLYDWHV&KNEXWQRWLQRFXODWLRQZLWK89LQDFWLYDWHG
(%9%DFWLYDWHV&KN(A7%&VZHUHLQRFXODWHGZLWK(%9%RU(%9*)302,&HOOVZHUHKDUYHVWHGDWWKHLQGLFDWHG
time points and expression of total Chk1 and pChk1 S345 or total Chk2 and pChk2 T68 was analyzed by western blot. Non-inoculated 
TBCs at 24 hours post isolation served as negative control, lymphoblastoid cell lines (LCLs) treated with Etoposide for 1 hour served as 
positive control. Detection of MRE11 served as loading control. The results shown are representative of 3 independent experiments. (B) 
TBCs where treated with 5 ng/mL CD40L, 20 ng/mL Il-4 and 200 ng/mL HA-antibody for 72 h. Expression of pATR, pChk1, pATM or 
pChk2 was analyzed by western blot. Non-inoculated TBCs at 24 hours post isolation served as negative control. Tubulin served as loading 
control (C) TBCs were inoculated with EBV-B95.8 or UV-EBV-B95.8 (MOI 8). Cells were harvested at the indicated time points and 
expression of pATR, pChk1, pATM or pChk2 was analyzed by western blotting. Non-inoculated TBCs at 24 hours post isolation served 
as negative control, lymphoblastoid cell lines (LCLs) treated with Etoposide for 6 hours served as positive control. Detection of ß-Actin 
served as loading control. The results shown are representative of 3 independent experiments.
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SL UHVXOWHG LQDGHFUHDVH LQ WUDQVIRUPDWLRQHI¿FLHQF\
compared to the vehicle control DMSO of ~ 1.5 and to ~ 
2.3 fold respectively (Figure 6A). By contrast, inhibition 
RI &KN GLG QRW DIIHFW (%9 WUDQVIRUPDWLRQ HI¿FLHQF\
neither at day 0 pi nor 4 pi compared to the DMSO control 
(Figure 6B). 
,Q FRQFOXVLRQ DFWLYDWLRQ RI$75 GXULQJ WKH ¿UVW
4 days pi, i.e. during the phase of hyperproliferation 
post EBV inoculation, seemed to be a key factor, which 
LQFUHDVHG(%9WUDQVIRUPDWLRQHI¿FLHQF\in vitro. Thus, 
factors impacting on this phase of vulnerability are 
likely to determine whether eventually EBV-induced 
transformation or PTLD occur.
DISCUSSION
Here, we investigated the role of the DNA damage 
response (DDR) pathways in controlling proliferation 
and transformation of TBCs during EBV primary 
infection using an in vitro system to model primary 
EBV infection of the EBV naïve host without and with 
immunosuppression, the latter close to primary B-cell 
infection in the immunosuppressed transplant recipient. 
We found that following inoculation with EBV (i) TBCs 
undergo a phase of hyperproliferation; (ii) in that phase 
TBCs express pATR and pChk1, suggesting that these 
abnormally proliferating cells experience replication 
stress; and (iii) ATR inhibition in TBCs decreases EBV’s 
WUDQVIRUPDWLRQ HI¿FLHQF\ 2XU UHVXOWV XQSUHFHGHQWHGO\
show how a cellular mechanism, aimed at protecting 
DNA from damage induced by abnormal cell proliferation, 
opens a vulnerable phase to transformation for the target 
cells following primary EBV infection of the host or of a 
B-cell. 
Remarkably, analysis of TBCs proliferation 
UHYHDOHG WKDW %FHOOV HQWHU WKHLU ¿UVW URXQG RI FHOOXODU
DNA replication only between 48 to 72 hours after 
EBV inoculation (Figure 1A). Subsequent mathematical 
analysis (Figure 1B) showed that TBCs undergo a phase 
of hyperproliferation between 48 and 96 hours post 
EBV inoculation. Our observation is comparable to the 
¿QGLQJVE\1LNLWLQet al. [11] who described a phase of 
hyperproliferation approximately between 2.5 and 4.5 days 
after EBV infection of peripheral blood B-cells in vitro. 
'XULQJK\SHUSUROLIHUDWLRQGH¿QHGDVDQDEQRUPDOO\KLJK
rate of cell division, there are higher chances for the cells 
to drive a faulty DNA replication. This can result in high 
level of replication stress and subsequently in activation of 
)LJXUH$75LQKLELWRUUHGXFHV(%9¶V%FHOOWUDQVIRUPDWLRQHI¿FLHQF\(A4XDQWL¿FDWLRQRI%FHOOVRXWJURZWKIROORZLQJ
tonsillar mononuclear cells (TMCs) infection with EBV-95.8 (3 fold serial dilution) in presence of vehicle control (0.01% of DMSO - black 
line) or 1 µM VE-821 ATR inhibitor (dottet-grey line) added at day 0 or 4 post EBV inoculation. (B4XDQWL¿FDWLRQRI%FHOOVRXWJURZWK
following TMCs in presence of vehicle control (0.01% DMSO - black line) or 10 nM of CHIR-124 Chk1 inhibitor (dotted-grey line) added 
at day 0 or 4 post EBV inoculation. The number of transformed wells is plotted relative to the transforming units (TU) of EBV-B95.8 per 
ZHOO5HVXOWVVKRZQDUHIURPGRQRUVDQGDUHSUHVHQWHGDVPHDQ6(0)RUERWK¿JXUH$DQG%WZR(%9SRVLWLYHDQGRQH(%9
negative donors were used. Dotted lines represent 62.5% positive wells. Based on a Poisson distribution this percentage represents the 
probability of B-cells outgrowth knowing that a viral particle is present in every well. *= p < 0.05 (Unpaired t-Test).
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DVWURQJDQGVSHFL¿F''5>@+XPDQ+HUSHVYLUXVKDV
been shown to induce activation of Chk1 72 hours pi [38], 
similarly to EBV (human herpes virus 4) as documented 
here. Thus, activation of an ATR/Chk1-dependent pathway 
LQ(%9LQRFXODWHG7%&VDVVKRZQKHUHIRUWKH¿UVWWLPH
might be an alternative mechanism of defense activated by 
target cells in the absence of a functional CTLs response 
limiting outgrowth and transformation of EBV-infected 
B-cells.
Of note, B-cells exhibited activation of ATR and 
Chk1 as indicated by phosphorylation of S428-ATR and 
S345-Chk1 (Figures 2A, 4A), which strictly coincided 
with the hyperproliferation phase following exposure 
to EBV. It has been shown that in response to CD40L/
IL4 stimulation B-cells undergo an initial burst of 
hyperproliferation similar to what has been described for 
EBV infection [33]. Since we observed similar activation 
of ATR and Chk1 in TBCs following stimulation with 
&'/,/)LJXUH%WKHSURFHVVLVQRW(%9VSHFL¿F
but rather a consequence of B-cell activation leading to 
replication stress. Nevertheless, the absence of ATR/
Chk1 activation when inoculating TBCs with UV-
inactivated EBV (Figure 5C) strongly implies that EBV 
needs to actively infect the target cell to induce ATR/Chk1 
activation. 
By contrast, TBCs did not exhibit detectable 
activation of ATM and Chk2 in any of our experiments 
(Figures 3A and 4A and 5A), suggesting absence of DSB 
leading to the activation of the required ATM/Chk2-
mediated DDR. Our results are at variance to those of 
Nikitin et al. [11] who observed activation of the ATM/
Chk2-mediated DDR in peripheral blood B-cells following 
EBV infection in vitro. One possible explanation could 
be the distinct EBV sources used in the experiments. We 
H[SRVHG7%&VWRDVHFRQG(%9VWUDLQ(%9*)3DQG
obtained the similar DDR pattern as we obtained with 
EBV-B95.8, suggesting that distinct EBV strains are 
not a very likely explanation for the results at variance. 
An alternative explanation could be the distinct sources 
of B-cells (TBCs versus peripheral blood B-cells). We 
executed the assessment of DDRs also with peripheral 
blood B-cells, but the results did not differ from those 
obtained with TBCs (Figure 4A). Thus, although the 
reason for the results at variance remains elusive, distinct 
experimental conditions but not the virus strains or the 
B-cell tissue origin are the most likely cause. 
$PRVWUHPDUNDEOHDQGVXUSULVLQJ¿QGLQJZDVWKH
reduced EBV in vitroWUDQVIRUPDWLRQHI¿FLHQF\REVHUYHG
after ATR inhibition (Figure 6A), indicated by the increase 
in the number of TUs necessary to transform 62.5% 
of cells after ATR inhibition. No such changes were 
detected after Chk1 inhibition (Figure 6B). Interestingly, 
Nikitin and colleagues [11] described that inhibition 
of ATM and Chk2 exhibited an opposite effect on EBV 
WUDQVIRUPDWLRQ HI¿FLHQF\ LQ SHULSKHUDO EORRG %FHOOV
LHDQLQFUHDVHGWUDQVIRUPDWLRQHI¿FLHQF\RI(%97KLV
VXJJHVWHGWKDWDFWLYDWLRQRI WKLVVSHFL¿F''5SDWKZD\
works as an alternative tumor suppressive pathway that 
regulates B-cell transformation. Thus, distinct activation 
RIVSHFL¿F''5VVHHPVWRKDYHGLYHUVHHIIHFWVRQ(%9
induced B-cell transformation in vitro. This, in turn, may 
imply that depending on the activated DDR upon EBV 
exposure in the absence of adaptive immune control of 
EBV-infected B-cells distinct outcomes of EBV-mediated 
B-cell transformation may arise. Further exploration of the 
mechanisms involved may reveal potential interventional 
WDUJHWV IRU SDWLHQWV ZLWK GH¿FLHQW LPPXQLW\ DJDLQVW
EBV, e.g., organ transplant recipients or HIV-infected 
individuals.
Even though EBV plays a crucial role in the 
development of PTLD, in vivo only 10% of the transplant 
recipients develop EBV-related lymphoma. Thus, 
additional factors might be required in order to induce 
PTLD [22]. One could speculate that previous bacterial 
or viral infections might stimulate TBCs proliferation 
leading to replication stress and consequently activation of 
the ATR/Chk1-mediated DDR, increasing the probability 
of EBV transformation by creating an environment 
promoting lymphoblastoid cell transformation by EBV. 
Indeed, it is known that TLRs signaling, including TLR9 
WKDW ELQG VSHFL¿F FRPPRQ SDWWHUQV RQ EDFWHULDO '1$
&S* PRWLIV FDQ GLUHFWO\ LQGXFH %FHOO SUROLIHUDWLRQ
[33, 39]. Furthermore, it has been shown in our lab that 
triggering of TLR9 signaling in a Burkitt’s lymphoma 
derived cell line blocks reactivation of EBV lytic cycle, 
reinforcing the risk of cell transformation [40]. Additional 
factors might also be required in vivo, in addition to ATR, 
WRVLJQL¿FDQWO\LQFUHDVHWKHULVNRI%FHOOWUDQVIRUPDWLRQ
by EBV. Those factors might be expressed only by certain 
individuals and therefore explain why PTLD is not more 
prevalent within the immunosuppressed patients. 
Taken together, our results indicate that activation 
RI WKHVSHFL¿F$75&KNPHGLDWHG''5SDWKZD\DQG
more precisely of ATR, is important to enhance EBV 
WUDQVIRUPDWLRQHI¿FLHQF\ LQ7%&V in vitro. In vivo, the 
immunocompetent host is able to keep hyperproliferating 
B-cells under control and EBV causes only very rarely 
B-cell tumors. By contrast, transplantation-related or 
otherwise highly immunosuppressed patients are at high 
risk of developing EBV-related PTLD upon primary 
(%9 LQIHFWLRQ:LWKRXW DQ HI¿FLHQW DGDSWLYH LPPXQH
system able to restrict proliferation of EBV-infected 
B-cells, those latter would not be restricted to undergo 
hyperproliferation. 
MATERIALS AND METHODS
Ethics statement
This study was conducted according to the principles 
expressed in the Declaration of Helsinki. The Cantonal 
Ethics Committee approved the study (StV29/06). All 
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subjects or their caregivers provided written informed 
consent for the collection of samples and subsequent 
analyses.
Cell culture
All cells were maintained in RPMI-1640 medium 
(Sigma-Aldrich, Buchs, Switzerland) supplemented 
with 10% heat-inactivated (hi) fetal bovine serum (FBS; 
/LIH 7HFKQRORJLHV7KHUPR )LVKHU 6FLHQWL¿F 5HLQDFK
6ZLW]HUODQG  P0 /*OXWDPLQH DQG  8PO 
 penicillin, and 100 µg/ml streptomycin, referred to 
hereafter as complete medium. All cells were cultured at 
37°C in 5% CO2 air of relative humidity > 95%.
Preparation of primary B-cells
Primary human tonsillar mononuclear cells (TMCs) 
were isolated from palatine tonsils obtained from pediatric 
patients who underwent tonsillectomy due to tonsillar 
hyperplasia. Tonsillar B-cells (TBCs) were prepared as 
GHVFULEHGSUHYLRXVO\>@%ULHÀ\WRQVLOVZHUHFXWLQWR
small pieces with a scalpel in phosphate-buffered saline 
3%6DQGSDVVHGWKURXJKDȝPSRUHVL]HFHOOVWUDLQHU
)DOFRQ:RKOHQ6ZLW]HUODQG7KHQ70&VZHUHSXUL¿HG
by density gradient centrifugation with Ficoll-Paque 
3UHPLXP9:5LQWHUQDWLRQDO*(+HDOWKFDUH'LHWLNRQ
Switzerland). TBCs were isolated from TMCs using the 
B-cell isolation kit II according to the instructions of 
WKHPDQXIDFWXUHU0LOWHQ\L%LRWHFK%HUJLVFK*ODGEDFK
*HUPDQ\7KHSXULW\RILVRODWLRQZDVDOZD\VRYHU
DVDVVHVVHGE\ÀRZF\WRPHWU\
Peripheral B-cells (PBCs) were isolated from 
blood form healthy donors and prepared as following. 
Buffycoats were diluted 5× with phosphate-buffered 
saline (PBS). Then, peripheral blood mononuclear cells 
3%0&VZHUHSXUL¿HGE\GHQVLW\JUDGLHQWFHQWULIXJDWLRQ
ZLWK )LFROO3DTXH 3UHPLXP 9:5 LQWHUQDWLRQDO*(
Healthcare). PBCs were isolated from PBMCs using the 
B-cell isolation kit II according to the instructions of the 
manufacturer (Miltenyi Biotech). 
3UHSDUDWLRQRIYLUXVVWRFNDQGTXDQWL¿FDWLRQ
The EBV-infected marmoset B95-8 were seeded at a 
density of 106 cells/ml and were stimulated to release virus 
by culture for 6–7 days in complete medium containing 
50 ng/ml of 12-Otetradecanoylphorbol-13-acetate (TPA; 
Sigma-Aldrich)/ml. Cell suspensions were centrifuged 
at 1000 × g for 10 min. Supernatant was passed through 
D  PSRUHVL]H FHOOXORVH DFHWDWH ¿OWHU 6DUVWHGW
6HYHOHQ6ZLW]HUODQGDQGVWRUHGDWí&
5HFRPELQDQW(%9*)3ZDVSURGXFHGLQFHOOV
DVGHVFULEHGHOVHZKHUH>@%ULHÀ\±FRQÀXHQW
HEK293-D2089 [42] cultured in DMEM supplemented 
ZLWK  KL)%6  /*OXWDPLQH  3HQLFLOOLQ
6WUHSWRP\FLQȝJPO+\JURP\FLQ%+\JUR*2/'
,QYLYR*HQ 7RXORXVH )UDQFH ZHUH WUDQVIHFWHG ZLWK
expression plasmids encoding the EBV gene BZLF1, 
DQG%$/)ȝJHDFKFPSODWHXVLQJ0HWDIHFWHQH
%LRQWH[ 0DUWLQVULHG3ODQHJJ *HUPDQ\ )RXU KRXUV
after transfection, the transfection mixture was replaced by 
fresh supplemented DMEM without Hygromycin B. Four 
days after transfection, supernatant was harvested, cleared 
E\FHQWULIXJDWLRQDW&ZLWKîJIRUPLQ¿OWHUHG
WKURXJKDȝP¿OWHUDQGVWRUHGDWí&
Concentrated virus stocks were prepared by 
centrifugation of viral supernatant with 30.000 × rpm 
for 2 hours at 4°C and resuspension of the virus pellet in 
complete medium (1/100 of the starting volume) and store 
DWí&
Ultraviolet (UV)-inactivated EBV-B95.8 was 
prepared by exposing 1.5 ml of concentrated virus stock 
for 15 min to a source of UV germicidal light.
Infection of primary B-cells and generation of 
lymphoblastoid cell lines (LCLs)
TBCs were centrifuged and resuspended in complete 
medium at a concentration of 2 × 106 cells/ml. B95.8 
culture supernatant prepared as described previously [23], 
(%9*)3RU89LQDFWLYDWHG(%9%ZDV DGGHG WR
each well at an MOI of 8. 
Freshly isolated TMCs or PBMCs were infected 
with 100 µl of B95-8 EBV and immediately treated with 
cyclosporin A (400 ng/ml; Sigma-Aldrich) to avoid killing 
RI(%9LQIHFWHGFHOOVE\(%9VSHFL¿F7FHOOV7KHFHOOV
were then seeded on a 96-wells plate and kept in culture 
for at least 5 weeks before expanding and freezing them in 
)&6'062DWí&
Proliferation assays
7%&VZHUHODEHOHGZLWK0FDUER[\ÀXRUHVFHLQ
diacetate succinimidyl ester (CFSE; Sigma-Aldrich) 
for 5 min at room temperature. The cells were then 
washed three times with PBS containing 5% hiFBS and 
resuspended in complete medium. The CFSE-labeled 
TBCs were inoculated with B95.8 culture supernatant and 
kept in culture. The cells were then harvested at indicated 
time points and analyzed by FACSCanto II (Becton 
Dickinson, Allschwil, Switzerland). The percentage of 
GLYLGHGFHOOVZDVFDOFXODWHGXVLQJ)ORZ-RSUROLIHUDWLRQ
platform and the mean division number was calculated as 
reported previously [24].
Western blotting
For western blotting whole cell lysate was prepared 
with 1% Triton X-100 Buffer (50 mM Tris-HCL, 150 mM 
1D&O7ULWRQ;P0(*7$P01D)P0
b-glycerolphosphate, 5 mM SodiumPyrophosphate, 1 mM 
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Na3VO4) supplemented with CompleteMini protease 
inhibitor (Roche Diagnostics, Rotkreuz, Switzerland). For 
the detection of primary antibodies, we used horseradish 
peroxidase-labeled goat anti-rabbit or horse anti-mouse 
antibodies (CellSignaling, Danvers, MA). Detection was 
performed using ECL western blotting detection reagents 
9:5LQWHUQDWLRQDO*(+HDOWKFDUHRU6XSHU6LJQDOZHVW
IHPWR NLW 7KHUPR )LVKHU 6FLHQWL¿F 7KH VLJQDO ZDV
GHWHFWHG XVLQJ WKH LPDJLQJ V\VWHP )XML¿OP /$6
LPDJHU)XML¿OP'LHOVGRUI6ZLW]HUODQG7KHGHQVLWRPHWU\
DQDO\VLVZDVSHUIRUPHGXVLQJWKH,PDJH-VRIWZDUH
RNA extraction and quantitative real-time 
polymerase chain reaction (qPCR)
Total RNA was extracted using the RNeasy 
Mini Kit (Qiagen, Basel, Switzerland) according to 
the manufacturer’s instructions. After DNaseI (DNA-
IUHH /LIH 7HFKQRORJLHV  7KHUPR )LVKHU 6FLHQWL¿F
WUHDWPHQWJȝJRIWRWDO51$ZDVXVHGDVWHPSODWH
for reverse transcription using a High-Capacity cDNA 
5HYHUVH 7UDQVFULSWLRQ .LW 7KHUPR )LVKHU 6FLHQWL¿F
*HQHH[SUHVVLRQRIChk1, ATR, Chk2, ATM and KAP1 
was determined using pre-validated primer/probes assay 
(Hs00992123_m1, Hs0967506_m1, Hs00200485_m1, 
Hs00175892_m1 and Hs00232212_m1 respectively; 
$SSOLHG %LRV\VWHPV  7KHUPR )LVKHU 6FLHQWL¿F $OO
reactions were performed on a 7900HT real-time 
PCR machine ((Applied Biosystems - Thermo Fisher 
6FLHQWL¿FZLWK7DT0DQ*HQH ([SUHVVLRQ0DVWHU0L[
7KHUPR)LVKHU6FLHQWL¿F7KHUHODWLYHJHQHH[SUHVVLRQ
was calculated for each gene of interest by using a 
ǻǻ&t method, where Ct values were normalized to the 
housekeeping genes 18s RNA.
&HOOF\FOHDQDO\VLVE\ÀRZF\WRPHWU\
TBCs inoculated with B95.8 were harvested at the 
indicated time point and washed with PBS. The cells were 
WKHQ¿[HGLQHWKDQRODQGNHSWDW&XQWLOVWDLQLQJ
$IWHU¿[DWLRQWKHFHOOVZHUHZDVKHGZLW3%6DQGVWDLQHG
with a propidium iodide (PI)-RNAseA solution (25 µg/
ml-0.1 mg/ml) for 30 min at 37°C. Stained samples were 
analyzed by FACS Canto II (Becton Dickinson, Allschwil, 
Switzerland). The results analysis was performed using the 
)ORZ-RVRIWZDUH
Cell viability assay
Viability of LCLs after VE-821 or CHIR-124 
treatments was assayed using WST-1 (water soluble 
tetrazolium-1) salt as a substrate, as described in the 
protocol supplied with the kit (Roche Diagnostics, 
Rotkreuz, Switzerland). The absorbance measured using 
a microplate reader (Bio-TEK instruments, Luzern, 
Switzerland) at 450 nm. Cell viability was calculated 
by Atreatment/Acontrol × 100 (A represents the absorbance 
recorded at 450 nm). 
Transformation assay
Infection of TMCs by EBV-B95.8 was performed 
in presence 400 ng/ml of cyclosporine A (Sigma Aldrich), 
0.01% DMSO, 1µM ATRi VE-821 (Selleckchem, Huston, 
TX) or 10 nM Chk1i CHIR-124 (Selleckchem) added at 
different times post infection (pi). TMCs were plated in 
24 wells of a 96 well plate and infected with different 
EBV concentration (MOI from 30 to 0.014, 3-fold serial 
dilution). The percentages of wells positive for B-cell 
transformation at 5 weeks post infection were plotted 
relative to the amount of virus used per well.
Antibodies
Primary antibodies used in these studies included 
rabbit anti-pChk2 (Thr68) (clone C13C1; Cell Signaling), 
rabbit anti-Chk2 (Cell Signaling), rabbit anti-pATR 
(Ser428) (Cell Signaling), rabbit anti-ATR (Cell 
Signaling), rabbit anti-pChk1 (Ser345) (clone 133D3; 
&HOO6LJQDOLQJUDEELWDQWLȕDFWLQ&HOO6LJQDOLQJPRXVH
DQWL$70FORQH&*HQH7H[,UYLQH&$UDEELWDQWL
.$3 *HQH7H[ UDEELW DQWLS.$3 6 %HWK\O
Montgomery, TX), rabbit anti-pATM (Ser1981) (Clone 
EP1890Y, Abcam, Cambridge, UK), mouse anti-Chk1 
FORQH*6DQWD&UX]+HLGHOEHUJ*HUPDQ\
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